1. Home
  2. MQY vs TYRA Comparison

MQY vs TYRA Comparison

Compare MQY & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniYield Quality Fund Inc.

MQY

Blackrock MuniYield Quality Fund Inc.

N/A

Current Price

$10.44

Market Cap

1.6B

Sector

Finance

ML Signal

N/A

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$19.83

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MQY
TYRA
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
MQY
TYRA
Price
$10.44
$19.83
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
★ $47.45
AVG Volume (30 Days)
★ 1.1M
573.7K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.67
$14.84
52 Week High
$11.94
$40.65

Technical Indicators

Market Signals
Indicator
MQY
TYRA
Relative Strength Index (RSI) 50.49 41.50
Support Level $9.73 $18.46
Resistance Level $10.47 $27.00
Average True Range (ATR) 0.15 1.15
MACD 0.01 0.05
Stochastic Oscillator 54.55 7.34

Price Performance

Historical Comparison
MQY
TYRA

About MQY Blackrock MuniYield Quality Fund Inc.

Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: